JP2024535053A - Ｖｉｓｔａ抗原結合性分子を使用する、がんの処置および防止 - Google Patents

Ｖｉｓｔａ抗原結合性分子を使用する、がんの処置および防止 Download PDF

Info

Publication number
JP2024535053A
JP2024535053A JP2024516963A JP2024516963A JP2024535053A JP 2024535053 A JP2024535053 A JP 2024535053A JP 2024516963 A JP2024516963 A JP 2024516963A JP 2024516963 A JP2024516963 A JP 2024516963A JP 2024535053 A JP2024535053 A JP 2024535053A
Authority
JP
Japan
Prior art keywords
amino acid
antigen
acid sequence
seq
binding molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024516963A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024535053A5 (enExample
Inventor
ボイド－カーカップ，ジェローム
グァン，シユ
パシュキェヴィチ，コンラッド
ロウィンスキー，エリック
タッカー，ディッティ
ダルマディカリ，ブーシャン
イングラム，ピアーズ
Original Assignee
ハミングバード・バイオサイエンス・プライベート・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハミングバード・バイオサイエンス・プライベート・リミテッド filed Critical ハミングバード・バイオサイエンス・プライベート・リミテッド
Publication of JP2024535053A publication Critical patent/JP2024535053A/ja
Publication of JP2024535053A5 publication Critical patent/JP2024535053A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2024516963A 2021-09-16 2022-09-16 Ｖｉｓｔａ抗原結合性分子を使用する、がんの処置および防止 Pending JP2024535053A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163244986P 2021-09-16 2021-09-16
US63/244,986 2021-09-16
PCT/EP2022/075849 WO2023041745A1 (en) 2021-09-16 2022-09-16 Treatment and prevention of cancer using vista antigen-binding molecules

Publications (2)

Publication Number Publication Date
JP2024535053A true JP2024535053A (ja) 2024-09-26
JP2024535053A5 JP2024535053A5 (enExample) 2025-09-19

Family

ID=83995418

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024516963A Pending JP2024535053A (ja) 2021-09-16 2022-09-16 Ｖｉｓｔａ抗原結合性分子を使用する、がんの処置および防止

Country Status (7)

Country Link
US (1) US20250313631A1 (enExample)
EP (1) EP4401772A1 (enExample)
JP (1) JP2024535053A (enExample)
KR (1) KR20240058149A (enExample)
CN (1) CN119384293A (enExample)
TW (1) TW202328196A (enExample)
WO (1) WO2023041745A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025125495A1 (en) 2023-12-13 2025-06-19 Hummingbird Bioscience Pte. Ltd. Treatment and prevention of cancer using vista antigen-binding molecules
GB202402901D0 (en) * 2024-02-29 2024-04-17 Cambridge Entpr Ltd reventative treatment of hrd associated cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014514346A (ja) * 2011-05-02 2014-06-19 ミレニアム ファーマシューティカルズ， インコーポレイテッド 抗α４β７抗体のための製剤
JP2015528464A (ja) * 2012-08-31 2015-09-28 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅＬＬＣ 抗体およびタンパク質製剤
JP2016533335A (ja) * 2013-09-27 2016-10-27 ジェネンテック， インコーポレイテッド 抗ｐｄｌ１抗体製剤
JP2021511818A (ja) * 2018-03-29 2021-05-13 ハミングバード・バイオサイエンス・ホールディングス・プライベート・リミテッド Ｖｉｓｔａ抗原結合性分子
JP2021531007A (ja) * 2018-07-20 2021-11-18 ピエール、ファーブル、メディカマン Ｖｉｓｔａに対する受容体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CN103119054B (zh) 2010-03-26 2017-01-18 达特茅斯大学理事会 Vista调节性t细胞介体蛋白、vista结合剂及其用途
ES2929575T3 (es) 2011-06-06 2022-11-30 Novo Nordisk As Anticuerpos terapéuticos
WO2014131694A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
EP3003390B1 (en) 2013-06-06 2021-07-07 Pierre Fabre Médicament Anti-c10orf54 antibodies and uses thereof
US10273301B2 (en) 2013-12-24 2019-04-30 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
MX2017007136A (es) 2014-12-05 2017-12-04 Immunext Inc Identificacion de vsig8 como el receptor vista putativo y su uso para producir moduladores vista/vsig8.
AU2016303485A1 (en) 2015-07-31 2018-03-01 Tarveda Therapeutics, Inc. Compositions and methods for immunomodulation
US10899836B2 (en) 2016-02-12 2021-01-26 Janssen Pharmaceutica Nv Method of identifying anti-VISTA antibodies
KR20250159733A (ko) 2017-01-11 2025-11-11 브리스톨-마이어스 스큅 컴퍼니 Psgl-1 길항제 및 그의 용도

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014514346A (ja) * 2011-05-02 2014-06-19 ミレニアム ファーマシューティカルズ， インコーポレイテッド 抗α４β７抗体のための製剤
JP2015528464A (ja) * 2012-08-31 2015-09-28 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅＬＬＣ 抗体およびタンパク質製剤
JP2016533335A (ja) * 2013-09-27 2016-10-27 ジェネンテック， インコーポレイテッド 抗ｐｄｌ１抗体製剤
JP2021511818A (ja) * 2018-03-29 2021-05-13 ハミングバード・バイオサイエンス・ホールディングス・プライベート・リミテッド Ｖｉｓｔａ抗原結合性分子
JP2021531007A (ja) * 2018-07-20 2021-11-18 ピエール、ファーブル、メディカマン Ｖｉｓｔａに対する受容体

Also Published As

Publication number Publication date
US20250313631A1 (en) 2025-10-09
WO2023041745A1 (en) 2023-03-23
TW202328196A (zh) 2023-07-16
KR20240058149A (ko) 2024-05-03
CN119384293A (zh) 2025-01-28
EP4401772A1 (en) 2024-07-24

Similar Documents

Publication Publication Date Title
JP7545438B2 (ja) Ｖｉｓｔａ抗原結合性分子
JP7545437B2 (ja) Ｈｅｒ３抗原結合性分子
US11873346B2 (en) VISTA antigen-binding molecules
JP2022548057A (ja) Ｈｅｒ３抗原結合性分子を使用したがんの処置および予防
WO2019185163A1 (en) Vista antigen-binding molecules
TWI917473B (zh) Bcma/taci抗原結合分子
US20260098093A1 (en) Treatment and prevention of cancer using vista antigen-binding molecules
US20250313631A1 (en) Treatment and prevention of cancer using vista antigen-binding molecules
US20250122303A1 (en) Treatment and prevention of cancer using her3 antigen-binding molecules
WO2023046979A1 (en) Treatment and prevention of cancer using vista antigen-binding molecules
WO2025125495A1 (en) Treatment and prevention of cancer using vista antigen-binding molecules
HK40026638B (en) Vista antigen-binding molecules
HK40026638A (en) Vista antigen-binding molecules

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250910

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250910

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260715

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260729